Abstract
Isoniazid (INH), rifampin (RIF), and pyrazinamide (PZA) are the most important drugs for the treatment of tuberculosis (TB). The pharmacokinetics of all three drugs in the plasma of 24 healthy males were studied as part of a randomized cross-over phase I study of two dosage forms. Subjects ingested single doses of INH at 250 mg, RIF at 600 mg, and PZA at 1,500 mg. Plasma was collected for 36 h and was assayed by high-performance liquid chromatography. The data were analyzed by noncompartmental, iterative two-stage maximum a posteriori probability Bayesian (IT2B) and nonparametric expectation maximization (NPEM) population modeling methods. Fast and slow acetylators of INH had median peak concentrations in plasma (C[max]) of 2.44 and 3.64 microg/ml, respectively, both of which occurred at 1.0 h postdose (time of maximum concentrations of drugs in plasma [T(max)]), with median elimination half-lives (t1/2) of 1.2 and 3.3 h, respectively (by the NPEM method). RIF produced a median C(max) of 11.80 microg/ml, a T(max) of 1.0 h, and a t1/2 of 3.4 h. PZA produced a median C(max) of 28.80 microg/ml, a T(max) of 1.0 h, and a t1/2 of 10.0 h. The pharmacokinetic behaviors of INH, RIF, and PZA were well described by the three methods used. These models can serve as benchmarks for comparison with models for other populations, such as patients with TB or TB with AIDS.
Full Text
The Full Text of this article is available as a PDF (221.6 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Berning S. E., Huitt G. A., Iseman M. D., Peloquin C. A. Malabsorption of antituberculosis medications by a patient with AIDS. N Engl J Med. 1992 Dec 17;327(25):1817–1818. doi: 10.1056/NEJM199212173272514. [DOI] [PubMed] [Google Scholar]
- Cockcroft D. W., Gault M. H. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31–41. doi: 10.1159/000180580. [DOI] [PubMed] [Google Scholar]
- Ellard G. A. Absorption, metabolism and excretion of pyrazinamide in man. Tubercle. 1969 Jun;50(2):144–158. doi: 10.1016/0041-3879(69)90020-8. [DOI] [PubMed] [Google Scholar]
- Houin G., Beucler A., Richelet S., Brioude R., Lafaix C., Tillement J. P. Pharmacokinetics of rifampicin and desacetylrifampicin in tuberculous patients after different rates of infusion. Ther Drug Monit. 1983;5(1):67–72. doi: 10.1097/00007691-198303000-00005. [DOI] [PubMed] [Google Scholar]
- Mouton R. P., Mattie H., Swart K., Kreukniet J., de Wael J. Blood levels of rifampicin, desacetylrifampicin and isoniazid during combined therapy. J Antimicrob Chemother. 1979 Jul;5(4):447–454. doi: 10.1093/jac/5.4.447. [DOI] [PubMed] [Google Scholar]
- Patel K. B., Belmonte R., Crowe H. M. Drug malabsorption and resistant tuberculosis in HIV-infected patients. N Engl J Med. 1995 Feb 2;332(5):336–337. doi: 10.1056/NEJM199502023320518. [DOI] [PubMed] [Google Scholar]
- Peloquin C. A., Berning S. E. Infection caused by Mycobacterium tuberculosis. Ann Pharmacother. 1994 Jan;28(1):72–84. doi: 10.1177/106002809402800115. [DOI] [PubMed] [Google Scholar]
- Peloquin C. A., James G. T., Craig L. D., Kim M., McCarthy E. A., Iklé D., Iseman M. D. Pharmacokinetic evaluation of aconiazide, a potentially less toxic isoniazid prodrug. Pharmacotherapy. 1994 Jul-Aug;14(4):415–423. [PubMed] [Google Scholar]
- Peloquin C. A., MacPhee A. A., Berning S. E. Malabsorption of antimycobacterial medications. N Engl J Med. 1993 Oct 7;329(15):1122–1123. doi: 10.1056/NEJM199310073291513. [DOI] [PubMed] [Google Scholar]
- Peloquin C. A., Nitta A. T., Burman W. J., Brudney K. F., Miranda-Massari J. R., McGuinness M. E., Berning S. E., Gerena G. T. Low antituberculosis drug concentrations in patients with AIDS. Ann Pharmacother. 1996 Sep;30(9):919–925. doi: 10.1177/106002809603000901. [DOI] [PubMed] [Google Scholar]
- Peloquin C. A. Therapeutic drug monitoring of the antimycobacterial drugs. Clin Lab Med. 1996 Sep;16(3):717–729. [PubMed] [Google Scholar]
- Sahai J., Gallicano K., Swick L., Tailor S., Garber G., Seguin I., Oliveras L., Walker S., Rachlis A., Cameron D. W. Reduced plasma concentrations of antituberculosis drugs in patients with HIV infection. Ann Intern Med. 1997 Aug 15;127(4):289–293. doi: 10.7326/0003-4819-127-4-199708150-00006. [DOI] [PubMed] [Google Scholar]
- Stottmeier K. D., Beam R. E., Kubica G. P. The absorption and excretion of pyrazinamide. I. Preliminary study in laboratory animals and in man. Am Rev Respir Dis. 1968 Jul;98(1):70–74. doi: 10.1164/arrd.1968.98.1.70. [DOI] [PubMed] [Google Scholar]